The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial

• Published in: EBioMedicine 2018-09, Vol.35, p.87-96
• Main Authors: Chen, Luyi, Xu, Wenli, Lee, Allen, He, Jiamin, Huang, Bixia, Zheng, Wenfang, Su, Tingting, Lai, Sanchuan, Long, Yanqin, Chu, Hua, Chen, Yujia, Wang, Lan, Wang, Kan, Si, Jianmin, Chen, Shujie
• Format: Article
• Language: English
• Subjects: 16S rRNA sequencing; Adult; Bismuth-containing quadruple therapy; Clostridium butyricum; Dietary Supplements; Disease Eradication; Female; Follow-Up Studies; Gastrointestinal Microbiome; Gut microbiota; Helicobacter Infections - microbiology; Helicobacter Infections - prevention & control; Helicobacter Infections - therapy; Helicobacter pylori; Helicobacter pylori - classification; Helicobacter pylori - physiology; Homeostasis; Humans; Male; Probiotics - administration & dosage; Research paper
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2018.08.028

Helicobacter pylori (H. pylori) infection is associated with remodeling of gastric microbiota. However, comprehensive analyses of the impact of H. pylori infection, eradication therapy and probiotic supplementation on gut microbiota are still lacking. We aimed to provide evidence for clinical decision making. Seventy H. pylori-positive and 35 H. pylori-negative patients (group C) were enrolled. H. pylori-positive patients were randomly assigned to group A (14-day bismuth-containing quadruple therapy) and group B (quadruple therapy supplemented with Clostridium butyricum). Stool samples of group A and B were collected on day 0, 14 and 56 while stool samples of group C were collected on day 0. Gut microbiota was investigated by 16S rRNA sequencing. The Sobs index (richness estimator) was significantly higher in H. pylori-positive samples than H. pylori-negative samples (p